C. Difficile Infection Video Perspectives

Jessica Allegretti, MD, MPH

Allegretti reports serving as a consultant for Abbvie, Adiso, Bristol Myer Squibb, Ferring, Finch Therapeutics, Iterative Scopes, Janssen, Merck, Pfizer, and Seres Therapeutics; as a speaker for Abbvie, BMS, and Janssen; and has received research support from Merck and Pfizer.
May 01, 2023
1 min watch
Save

VIDEO: Current treatment options for C. difficile infection

Transcript

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Currently, to treat C. diff infection, the only options we still have are antibiotics. And so antibiotics for C. diff, the mainstay right now, based on both the IDSA and ACG guidelines are either vancomycin or fidaxomicin for a first episode of C. diff. Now, in a recent update, the Infectious Disease Society did state that they recommended fidaxomicin preferentially over vancomycin. In the American College of Gastro guidelines, they are both felt to be equivalent, essentially, for use of treating primary C. diff, regardless of severity, so both primary non-severe and primary severe.